Literature DB >> 32441006

Predictive model of surgical remission in acromegaly: age, presurgical GH levels and Knosp grade as the best predictors of surgical remission.

M Araujo-Castro1, E Pascual-Corrales2, V Martínez-Vaello2, G Baonza Saiz2, J Quiñones de Silva2, A Acitores Cancela3, A M García Cano4, V Rodríguez Berrocal3,5.   

Abstract

PURPOSE: To identify presurgical clinical, hormonal and radiological variables associated with surgical remission in acromegaly and develop a predictive model for surgical remission.
METHODS: Ambispective study of acromegaly surgical patients followed in two Spanish tertiary hospitals. Patients operated by the same neurosurgeon by endonasal endoscopic transsphenoidal approach (n = 49) were included to develop the predictive model, and patients operated by other neurosurgeons (n = 37) were used for external validation of the predictive model. The predictive model was developed with a multivariate logistic regression model based on the 2000 criteria.
RESULTS: 86 acromegalic patients were included. 49 patients, 83.7% with macroadenomas and 32.7% with Knosp grade > 2, were included for the development of the predictive model. The overall rate of surgical remission with the 2000 criteria was 73.5% and 51.0% with the 2010 criteria. Using the 2000 criteria, variables associated with surgical remission were: older age (OR = 1.1, p = 0.001), lower basal presurgical GH levels (OR = 0.9, p = 0.003), Knosp 0-2 (OR = 34.1, p < 0.0001) and lower maximum pituitary adenoma diameter (OR = 0.9, p = 0.019). The model with the best diagnostic accuracy to predict surgical remission combined age, Knosp 0-2 and presurgical GH levels (AIC = 29.7, AUC = 0.95) with a sensitivity of 93.8% and a specificity of 75.0%. The estimated loss of prediction with the external validation (n = 37) was 4.2%.
CONCLUSION: The predictive model with the best diagnosis accuracy for surgical remission combined age, Knosp 0-2 and presurgical GH levels, with a sensitivity of 93.8% and a specificity of 75.0%. This model could be very useful to select candidates to preoperative medical treatment and planning the follow-up.

Entities:  

Keywords:  Acromegaly; Pituitary tumour; Predictive model; Surgical remission; Transsphenoidal surgery

Year:  2020        PMID: 32441006     DOI: 10.1007/s40618-020-01296-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results.

Authors:  A Abosch; J B Tyrrell; K R Lamborn; L T Hannegan; C B Applebury; C B Wilson
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

Review 2.  Acromegaly: assessing the disorder and navigating therapeutic options for treatment.

Authors:  Shlomo Melmed; David L Kleinberg; Vivien Bonert; Maria Fleseriu
Journal:  Endocr Pract       Date:  2014-10       Impact factor: 3.443

3.  Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.

Authors:  John A Jane; Robert M Starke; Mohamed A Elzoghby; Davis L Reames; Spencer C Payne; Michael O Thorner; John C Marshall; Edward R Laws; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06-29       Impact factor: 5.958

Review 4.  GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis.

Authors:  I A Franzini; F M Yamamoto; F Bolfi; S R Antonini; V S Nunes-Nogueira
Journal:  Eur J Endocrinol       Date:  2018-12-01       Impact factor: 6.664

5.  Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.

Authors:  M Terzolo; S Bossoni; A Alí; M Doga; G Reimondo; G Milani; P Peretti; F Manelli; A Angeli; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

6.  A consensus on criteria for cure of acromegaly.

Authors:  A Giustina; P Chanson; M D Bronstein; A Klibanski; S Lamberts; F F Casanueva; P Trainer; E Ghigo; K Ho; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

7.  Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience.

Authors:  Nadia Hameed; Chris G Yedinak; Jessica Brzana; Sakir H Gultekin; Nicholas D Coppa; Aclan Dogan; Johnny B Delashaw; Maria Fleseriu
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

8.  An audit of outcome of treatment in acromegaly.

Authors:  A S Bates; W Van't Hoff; J M Jones; R N Clayton
Journal:  Q J Med       Date:  1993-05

9.  Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.

Authors:  Akio Ohta; Kaori Arai; Ami Nishine; Yoshiyuki Sada; Hiroyuki Kato; Hisashi Fukuda; Shiko Asai; Yoshio Nagai; Takuyuki Katabami; Yasushi Tanaka
Journal:  Endocr J       Date:  2012-10-06       Impact factor: 2.349

10.  Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).

Authors:  Antonio Mestron; Susan M Webb; Ricardo Astorga; Pedro Benito; Miguel Catala; Sonia Gaztambide; Jose-Manuel Gomez; Irene Halperin; Tomas Lucas-Morante; Basilio Moreno; Gabriel Obiols; Pedro de Pablos; Concha Paramo; Antonio Pico; Elena Torres; Cesar Varela; Jose-Antonio Vazquez; Juana Zamora; Merce Albareda; Montserrat Gilabert
Journal:  Eur J Endocrinol       Date:  2004-10       Impact factor: 6.664

View more
  6 in total

1.  Effect of pituitary adenoma consistency on surgical outcomes in patients undergoing endonasal endoscopic transsphenoidal surgery.

Authors:  A Acitores Cancela; V Rodríguez Berrocal; H Pian Arias; J J Díez; P Iglesias
Journal:  Endocrine       Date:  2022-08-13       Impact factor: 3.925

2.  Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas.

Authors:  Marta Araujo-Castro; Héctor Pian; Ignacio Ruz-Caracuel; Alberto Acitores Cancela; Eider Pascual-Corrales; Víctor Rodríguez Berrocal
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

3.  Analysis of Related Factors of Tumor Recurrence or Progression After Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis.

Authors:  Yike Chen; Feng Cai; Jing Cao; Feng Gao; Yao Lv; Yajuan Tang; Anke Zhang; Wei Yan; Yongjie Wang; Xinben Hu; Sheng Chen; Xiao Dong; Jianmin Zhang; Qun Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-14       Impact factor: 5.555

4.  Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.

Authors:  Tyler Cardinal; Casey Collet; Michelle Wedemeyer; Peter A Singer; Martin Weiss; Gabriel Zada; John D Carmichael
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

5.  Radiological Knosp, Revised-Knosp, and Hardy-Wilson Classifications for the Prediction of Surgical Outcomes in the Endoscopic Endonasal Surgery of Pituitary Adenomas: Study of 228 Cases.

Authors:  Marta Araujo-Castro; Alberto Acitores Cancela; Carlos Vior; Eider Pascual-Corrales; Víctor Rodríguez Berrocal
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

6.  Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.

Authors:  Agnieszka Tomasik; Maria Stelmachowska-Banaś; Maria Maksymowicz; Izabella Czajka-Oraniec; Dorota Raczkiewicz; Grzegorz Zieliński; Jacek Kunicki; Wojciech Zgliczyński
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-16       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.